TOX2 and neoplasm: Moreover, in a chimeric antigen receptor-T cell (CAR-T) therapy tumor model, it was found that CAR-T cells doubly deficient for both TOX and TOX2 (TOX DKO) are more effective than either TOX-deficient or TOX2-deficient CAR-TILs (tumor-infiltrating lymphocytes) in suppressing tumor growth and prolonging the survival of tumor-bearing mice.